Dr. Elizabeth Stoner, M.D., M.S., has been appointed as a Class II director and member of the Compensation Committee, effective May 7, 2026. Dr. Stoner replaces Evert Schimmelpennink, who resigned from the Board effective May 7, 2026. The appointment coincides with the company's transition toward becoming a clinical-stage biotechnology firm. Dr. Stoner will receive standard non-employee director compensation, including a $40,000 annual board fee and a $7,500 annual committee fee, plus equity grants.